Navigation Links
Anesiva to Present at BioCentury Newsmakers Conference on September 4, 2008
Date:8/29/2008

SOUTH SAN FRANCISCO, Calif., Aug. 29 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that Michael L. Kranda, the company's president and chief executive officer, will present at BioCentury's Newsmakers in the Biotech Industry Conference in New York City on September 4, 2008 at 2:00 p.m. ET.

To access the live webcast or the subsequent archived recording, log on to http://www.anesiva.com, go to the Investors page, and click on Events. Please connect to Anesiva's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Anesiva and its Diverse Pipeline of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel pharmaceutical products for pain management. The company's first commercial product, Zingo(TM), is available in the U.S. for the reduction of pain associated with peripheral venous access procedures in children ages three to 18. For full Zingo prescribing information and other information, visit http://www.zingo.com. An sNDA is under review at FDA to expand the Zingo label indication to include adults.

The next product in Anesiva's pipeline, Adlea(TM), is currently being evaluated in Phase 3 clinical trials for the management of acute pain following orthopedic surgeries. Adlea has been shown to reduce pain after only a single administration for up to weeks to months in multiple settings based on the results of several mid-stage clinical trials for site-specific, acute and chronic, moderate-to-severe pain.

Anesiv
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Anesiva Announces Second Quarter 2008 Financial Results and Update
2. Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
3. Anesiva Names Michael L. Kranda as President, Chief Executive Officer and Member of Its Board of Directors
4. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
5. Anesiva Announces First Quarter 2008 Financial Results
6. Anesiva Announces First Quarter 2008 Financial Results Conference Call and Webcast
7. Anesiva Announces Expansion of Zingo Agreement in Europe
8. Anesiva Announces New Zingo Marketing and Distribution Agreement
9. Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
10. Anesiva Announces March 5, 2008 Presentation at Susquehanna Financial Group Healthcare Conference
11. Anesiva Announces Fourth Quarter and Year-End 2007 Financial Results and Provides 2008 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Understanding the need for better quality and ... gap that currently exists in this area, ChanTest has ... of validated ion channel and GPCR cell lines. ... ion channels control many critical physiological functions throughout the ... potential to treat a variety of human diseases. ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 EvoDerma ’s ... convenience. This rejuvenating device now comes with a second treatment ... over time. , The new cup is thinner on the ... works to target rough, thin and uneven surfaces on the ... cup for a stimulating treatment on areas such as the ...
(Date:7/10/2014)... July 10, 2014 /PRNewswire-iReach/ -- Tute Genomics, ... today announced an agreement with Lineagen, Inc., ... Lineagen,s NextStep Dx PLUS.  Lineagen, focused ... neurological disorders, currently offers FirstStep Dx ... service used by healthcare providers as a ...
(Date:7/10/2014)... microscopic polymer light resonators that expand in the ... Photonics Laboratory have developed new optical sensors with ... sensors are ideal for detecting trace gas concentrations ... nature, and immunity to electromagnetic interference. , Although ... the MIT team conceived an extremely sensitive, compact ...
Breaking Biology Technology:Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Swell new sensors 2
... ... Presence in China, CAMBRIDGE, Mass., April 22 ... a major new research and,development center in Beijing. The initiative is ... a,long-term presence in China., The new facility will be used ...
... to Threat of Bioterrorism, Says UK Board ... Member General Lord Guthrie, ... to develop and deploy technology that can neutralize and destroy,a biohazardous ... has partnered with General Lord Guthrie,former chief of the British Defense ...
... April 22 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc.,(,Lorus,), ... and,development of pharmaceutical products and technologies for ... of a development program aimed at,expanding the ... for the treatment of superficial bladder cancer., ...
Cached Biology Technology:Genzyme to Build New R&D Center in Beijing 2Genzyme to Build New R&D Center in Beijing 3Genzyme to Build New R&D Center in Beijing 4Genzyme to Build New R&D Center in Beijing 5Boston-Based BioDefense Corp. Announces New UK Partnership to Expand Markets for Biohazard Protection 2Boston-Based BioDefense Corp. Announces New UK Partnership to Expand Markets for Biohazard Protection 3Lorus initiates development program exploring novel route of administration for LOR-2040 2Lorus initiates development program exploring novel route of administration for LOR-2040 3Lorus initiates development program exploring novel route of administration for LOR-2040 4
(Date:7/10/2014)... of enzymes known as heme enzymes, due to the ... At the centre of the heme cofactor is an ... reacting heme is in an intermediate state called Compound ... is whether this oxidation involves just an oxygen atom ... question has implications for understanding oxidative processes within living ...
(Date:7/10/2014)... (ACS) announced today that Courtney Aldrich, Ph.D., will ... Diseases as editor-in-chief. With the first issue ... journal will meet a growing demand for a ... , "Our vision is to develop a journal ... the basic science that advances the field and ...
(Date:7/10/2014)... from The University of Texas Health Science Center at ... (IYG), a health education program designed to delay sexual ... dating violence behaviors among minority youth. , According to ... of high school youth are victims of physical dating ... percent are victims of emotional dating violence. Previous studies ...
Breaking Biology News(10 mins):Neutron crystallography solves long-standing biological mystery 2Neutron crystallography solves long-standing biological mystery 3ACS Infectious Diseases: Unique chemistry journal names editor 2It's Your Game ... Keep It Real reduces dating violence among minority youth 2
... NEW YORK, February 4, 2011 A defining feature ... today,s age of computational science, this means higher standards ... that generated the results along with the published research ... widely accessible, facilitating re-use and verification of results. ...
... the annual meeting of the American Association for the Advancement ... climate change could increase exposure and risk of human illness ... studies projecting impacts to be felt within 30 years. ... warmest for sea surface temperatures, NOAA and our partners are ...
... Among the many differences between girls and boys, add the ... the list. , Results of a double-blind, placebo-controlled, dose-response study ... general, boys get a greater rush and more energy from ... caffeine had a positive effect on their athletic performance. Girls ...
Cached Biology News:AAAS Symposium: New research facilitates scientific knowledge transfer 2Climate projections show human health impacts possible within 30 years 2Climate projections show human health impacts possible within 30 years 3Climate projections show human health impacts possible within 30 years 4High-caffeine-consuming boys get greater rush from caffeine than girls 2High-caffeine-consuming boys get greater rush from caffeine than girls 3
...
Jak3 Antibody Ship: Hot Store: -20 C...
WASF2 Immunogen: WASF2 (NP_008921, 73 a.a. ~ 173 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Applications: Western blotting Stability: Room temperature, indefinitely ...
Biology Products: